.png)
Being diagnosed with early-stage breast cancer often raises many questions. One of the first things that may come to mind is: Do I have to undergo chemotherapy? Is it possible to recover without chemotherapy? What are the chances of recovery?
These questions are completely understandable. Every patient’s condition is different, which means treatment decisions cannot be generalized. The stage of cancer, the biological characteristics of the tumor, and the patient’s overall health condition all play an important role in determining treatment recommendations and recovery outcomes.
How Likely Is Breast Cancer to Recur?
Breast cancer recurrence refers to a condition where cancer returns after treatment has been completed and was previously undetectable. This can happen when a small number of cancer cells remain in the body after the initial therapy and gradually grow over time. Recurrence may occur in the same area (local recurrence), in nearby lymph nodes, or in other organs.
Every patient who has undergone breast cancer treatment has a possibility of recurrence, although the level of risk varies. In early-stage breast cancer, especially stage 1, the chances of remaining cancer-free are generally very good. According to data from the American Cancer Society and the National Cancer Institute, with appropriate treatment, the 5-year survival rate for early-stage breast cancer can reach more than 90–99%. However, a small number of patients may still experience recurrence.
The risk of recurrence is influenced by several factors, including tumor size, lymph node involvement, the aggressiveness of cancer cells, and biological characteristics such as hormone receptor status and HER2 status. Most recurrences occur within the first few years after treatment, although in some cases cancer can return many years later.
For this reason, understanding the risk of recurrence is an important step in determining the next stage of treatment. This risk assessment helps doctors decide whether additional therapy, including chemotherapy, is truly necessary.
Genomic Testing to Determine Whether Chemotherapy Is Needed
In early-stage breast cancer, not all patients require chemotherapy. To help determine whether chemotherapy will provide meaningful benefit, doctors can now use genomic tests that analyze gene activity in tumor tissue.
These tests help predict the risk of cancer recurrence and estimate whether a patient is likely to benefit from chemotherapy. With this information, doctors can make more informed treatment decisions based on the biological characteristics of the cancer, rather than relying solely on tumor size or disease stage.
Avoiding Unnecessary Treatment
One of the key advantages of genomic testing is helping to avoid overtreatment, which refers to treatments that may not provide significant benefit for the patient.
While chemotherapy is effective at killing cancer cells, it can also cause side effects such as fatigue, nausea, hair loss, and immune system suppression. Therefore, if the risk of recurrence is considered low, some patients may not need chemotherapy and can instead pursue other treatments that are more suitable for their condition.
Treatment Strategies Based on Tumor Biology
Breast cancer treatment is increasingly moving toward personalized medicine, where therapy is tailored to the biological profile of each patient’s cancer. By understanding the tumor’s characteristics more deeply, doctors can determine the most appropriate treatment strategy for each individual.
One genomic test that supports this approach is MammaPrint, which analyzes the activity of 70 genes in tumor tissue to classify the risk of recurrence as either low risk or high risk. This information can help doctors and patients evaluate treatment options, including whether chemotherapy is truly necessary or may be safely avoided.
As part of a more comprehensive breast cancer evaluation, MammaPrint can serve as an important tool for understanding a patient’s risk profile in a more personalized way. As a result, treatment decisions are not based solely on cancer stage but also on the biological characteristics of the tumor.
To support a more precise diagnostic approach, KALGen Innolab, as a diagnostic laboratory, provides genomic testing services such as MammaPrint to help assess the risk of breast cancer recurrence more accurately. Supported by advanced diagnostic technology and experienced medical professionals, this test can provide valuable information to assist doctors and patients in planning a more appropriate and targeted treatment strategy.
Conclusion
In early-stage breast cancer, chemotherapy is not always the only treatment option. The decision to undergo chemotherapy should consider several factors, including the risk of recurrence, the biological characteristics of the tumor, and the patient’s overall health condition.
With advances in medical technology, genomic testing can now help assess recurrence risk more accurately and predict whether a patient is likely to benefit from chemotherapy. This information enables doctors and patients to make more informed treatment decisions, avoid unnecessary therapies, and design more personalized treatment strategies based on the unique characteristics of each patient’s cancer.
References
American Cancer Society. (2024). Breast cancer survival rates. https://www.cancer.org/cancer/types/breast-cancer/detection-diagnosis-staging/survival-rates-for-breast-cancer.html
National Cancer Institute. (2023). Breast cancer treatment (PDQ®)–Patient version. https://www.cancer.gov/types/breast/patient/breast-treatment-pdq
National Cancer Institute. (2023). Breast cancer—Patient version. https://www.cancer.gov/types/breast
Cleveland Clinic. (2023). Breast cancer recurrence. https://my.clevelandclinic.org/health/diseases/8328-breast-cancer-recurrence
U.S. National Library of Medicine. (2023). Breast cancer recurrence. In MedlinePlus Medical Encyclopedia. https://medlineplus.gov/ency/article/007214.htm
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2017). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 18(1), 27–39. https://doi.org/10.1016/S1470-2045(16)30477-4
.png)
